Document is current
Any future updates will be listed below
-
Authors
Dong, Shuxian http://orcid.org/0000-0003-4725-8482
Wang, Qian
Kao, Yun-Ruei
Diaz, Antonio
Tasset, Inmaculada
Kaushik, Susmita http://orcid.org/0000-0002-6096-5387
Thiruthuvanathan, Victor
Zintiridou, Aliona
Nieves, Edward
Dzieciatkowska, Monika
Reisz, Julie A.
Gavathiotis, Evripidis http://orcid.org/0000-0001-6319-8331
D’Alessandro, Angelo http://orcid.org/0000-0002-2258-6490
Will, Britta http://orcid.org/0000-0002-9534-6690
Cuervo, Ana Maria http://orcid.org/0000-0002-0771-700X
-
License Information
Text and Data Mining valid from 2021-01-13
Version of Record valid from 2021-01-13
-
More Information
Article History
Received: 28 December 2019
Accepted: 9 December 2020
First Online: 13 January 2021
Competing interests
: A.M.C. and E.G. are cofounders of Selphagy Therapeutics (Boston, MA, USA). The CA compound is under the following patent: Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof. Gavathiotis, E., Cuervo. A. M., Xin, Q., Das, B. C. United States patent US9512092, granted 16 December 2016. All other authors declare no competing interests.
